Inari Medical FY2027 EPS Estimate Cut by Leerink Partnrs

Inari Medical, Inc. (NASDAQ:NARI) – Equities researchers at Leerink Partnrs reduced their FY2027 earnings per share (EPS) estimates for shares of Inari Medical in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of $0.54 for the year, down from their previous estimate of $0.56. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.77) per share. Leerink Partnrs also issued estimates for Inari Medical’s FY2028 earnings at $0.97 EPS.

A number of other equities analysts have also weighed in on NARI. Truist Financial raised their target price on shares of Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a research note on Tuesday, October 29th. Canaccord Genuity Group raised their price objective on Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Piper Sandler increased their price target on Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a research note on Tuesday, October 29th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Inari Medical in a research note on Friday, August 9th. They issued a “buy” rating and a $68.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $58.89.

Inari Medical Price Performance

Shares of NARI opened at $49.48 on Tuesday. The firm has a market cap of $2.90 billion, a P/E ratio of -36.65 and a beta of 0.96. Inari Medical has a 1 year low of $36.73 and a 1 year high of $67.13. The company has a 50 day simple moving average of $45.66 and a two-hundred day simple moving average of $47.33.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. GAMMA Investing LLC lifted its stake in shares of Inari Medical by 164.7% during the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after acquiring an additional 438 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after purchasing an additional 435 shares during the period. KBC Group NV boosted its stake in shares of Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after purchasing an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after purchasing an additional 522 shares during the last quarter. Finally, Covestor Ltd increased its stake in Inari Medical by 63.5% in the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after buying an additional 926 shares during the period. Institutional investors own 90.98% of the company’s stock.

Insider Activity at Inari Medical

In other Inari Medical news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the transaction, the director now owns 643,296 shares in the company, valued at $29,482,255.68. The trade was a 5.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares of the company’s stock, valued at $22,265,500. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 186,000 shares of company stock worth $8,990,990. Company insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.